Shares of Acorda Therapeutics were higher on April 15, one day after trading was halted amid rumors of a patent extension for the ACOR's multiple sclerosis Ampyra.
In Friday trading ACOR stock price was up $2.02 (7.45%) to post a closing quote of $29.15 a share.
Acorda Therapeutics
Shares of Acorda Therapeutics Inc. rallied today on news and rumors of a patent extension for the Acorda drug Ampyra. Ampyra is a multiple sclerosis drug and Acorda is seeking to extend the patent until 2024.
The U.S. Patent and Trademark Office issued an update on its website titled "reasons for allowance" in reference to the Acorda Ampyra patent issue.
There is speculation that an extension of the patent date would also make Acorda Therapeutics an attractive takeover or buyout target.
In 2010 Ampyra generated revenue last year of $133.1 million for Acorda Therapeutics.
ACOR stock price gained 26.66% or $5.71 a share to quote a price of $27.13 before trading was halted on the NASDAQ.
Acorda Therapeutics
